Regulation of Octn2 transporter (SLC22A5) by peroxisome proliferator activated receptor alpha. 2008

Tomoji Maeda, and Takeru Wakasawa, and Miho Funabashi, and Akimasa Fukushi, and Masaharu Fujita, and Kiyoto Motojima, and Ikumi Tamai
Department of Membrane Transport and Pharmacokinetics, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Chiba, Japan.

The tissue distribution and disposition of carnitine, which plays an important role in the transport of long-chain fatty acids across the mitochondrial inner membrane for beta-oxidation, are well controlled by carnitine transporter organic cation/carnitine transporter 2 (OCTN2). Since little information is available on regulation of the expression of the OCTN2 gene, we examined the factors that affect the expression level of rat Octn2 (rOctn2), focusing on nuclear receptor peroxisome proliferator activated receptor alpha (PPARalpha), which regulates expression of genes associated with beta-oxidation of fatty acids. mRNA of rOctn2 was induced by the PPARalpha ligand fenofibrate in primary-cultured rat hepatocytes. Further, the PPARalpha ligand Wy14643 increased the expression of Octn2 in wild-type mice, but not in PPARalpha knockout mice. Analysis of the rOctn2 promoter region suggested the presence of putative cis elements of PPARalpha. Wistar rats treated with intraperitoneal fenofibrate administration showed increased expression of rOctn2 mRNA in liver, and uptake of [3H]carnitine by freshly isolated hepatocytes derived from those rats was also increased. In conclusion, our results indicate that the nuclear receptor PPARalpha directly up-regulates the expression of rOctn2 and increases the hepatic uptake of carnitine via rOctn2.

UI MeSH Term Description Entries
D008156 Luciferases Enzymes that oxidize certain LUMINESCENT AGENTS to emit light (PHYSICAL LUMINESCENCE). The luciferases from different organisms have evolved differently so have different structures and substrates. Luciferase
D008297 Male Males
D010957 Plasmids Extrachromosomal, usually CIRCULAR DNA molecules that are self-replicating and transferable from one organism to another. They are found in a variety of bacterial, archaeal, fungal, algal, and plant species. They are used in GENETIC ENGINEERING as CLONING VECTORS. Episomes,Episome,Plasmid
D011345 Fenofibrate An antilipemic agent which reduces both CHOLESTEROL and TRIGLYCERIDES in the blood. Procetofen,Antara Micronized Procetofen,Apo-Feno-Micro,Apo-Fenofibrate,CiL,Controlip,Fenobeta,Fenofanton,Fenofibrat AL,Fenofibrat AZU,Fenofibrat AbZ,Fenofibrat FPh,Fenofibrat Heumann,Fenofibrat Hexal,Fenofibrat Stada,Fenofibrat-ratiopharm,Fénofibrate Debat,Fénofibrate MSD,Gen-Fenofibrate,LF-178,Lipanthyl,Lipantil,Liparison,Lipidil,Lipidil-Ter,Livesan,Lofibra,MTW-Fenofibrat,Normalip,Novo-Fenofibrate,Nu-Fenofibrate,PMS-Fenofibrate Micro,Phenofibrate,Procetofene,Secalip,Supralip,Tricor,durafenat,fenofibrat von ct,AZU, Fenofibrat,Apo Feno Micro,Apo Fenofibrate,Debat, Fénofibrate,Fenofibrat ratiopharm,Gen Fenofibrate,Heumann, Fenofibrat,Hexal, Fenofibrat,LF 178,LF178,Lipidil Ter,MTW Fenofibrat,Micronized Procetofen, Antara,Novo Fenofibrate,Nu Fenofibrate,PMS Fenofibrate Micro,Procetofen, Antara Micronized,Stada, Fenofibrat
D011401 Promoter Regions, Genetic DNA sequences which are recognized (directly or indirectly) and bound by a DNA-dependent RNA polymerase during the initiation of transcription. Highly conserved sequences within the promoter include the Pribnow box in bacteria and the TATA BOX in eukaryotes. rRNA Promoter,Early Promoters, Genetic,Late Promoters, Genetic,Middle Promoters, Genetic,Promoter Regions,Promoter, Genetic,Promotor Regions,Promotor, Genetic,Pseudopromoter, Genetic,Early Promoter, Genetic,Genetic Late Promoter,Genetic Middle Promoters,Genetic Promoter,Genetic Promoter Region,Genetic Promoter Regions,Genetic Promoters,Genetic Promotor,Genetic Promotors,Genetic Pseudopromoter,Genetic Pseudopromoters,Late Promoter, Genetic,Middle Promoter, Genetic,Promoter Region,Promoter Region, Genetic,Promoter, Genetic Early,Promoter, rRNA,Promoters, Genetic,Promoters, Genetic Middle,Promoters, rRNA,Promotor Region,Promotors, Genetic,Pseudopromoters, Genetic,Region, Genetic Promoter,Region, Promoter,Region, Promotor,Regions, Genetic Promoter,Regions, Promoter,Regions, Promotor,rRNA Promoters
D002331 Carnitine A constituent of STRIATED MUSCLE and LIVER. It is an amino acid derivative and an essential cofactor for fatty acid metabolism. Bicarnesine,L-Carnitine,Levocarnitine,Vitamin BT,L Carnitine
D002469 Cell Separation Techniques for separating distinct populations of cells. Cell Isolation,Cell Segregation,Isolation, Cell,Cell Isolations,Cell Segregations,Cell Separations,Isolations, Cell,Segregation, Cell,Segregations, Cell,Separation, Cell,Separations, Cell
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D000074058 Solute Carrier Family 22 Member 5 A high-affinity, ATP-binding, co-transporter for CARNITINE that is highly expressed in kidney, skeletal muscle, heart, and placental tissues. It transports one sodium ion with one carnitine molecule. It has a lower affinity for other organic cations and transports them independently of sodium. Mutations in the SLC22A5 gene are associated with systemic carnitine deficiency. High-Affinity Carnitine Transporter,OCTN2 Protein,Organic Cation-Carnitine Transporter 2,SLC22A5 Protein,Sodium-Dependent Carnitine Cotransporter,Carnitine Cotransporter, Sodium-Dependent,Carnitine Transporter, High-Affinity,High Affinity Carnitine Transporter,Organic Cation Carnitine Transporter 2,Sodium Dependent Carnitine Cotransporter,Transporter, High-Affinity Carnitine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Tomoji Maeda, and Takeru Wakasawa, and Miho Funabashi, and Akimasa Fukushi, and Masaharu Fujita, and Kiyoto Motojima, and Ikumi Tamai
March 2009, Toxicological sciences : an official journal of the Society of Toxicology,
Tomoji Maeda, and Takeru Wakasawa, and Miho Funabashi, and Akimasa Fukushi, and Masaharu Fujita, and Kiyoto Motojima, and Ikumi Tamai
August 2005, Biochemistry,
Tomoji Maeda, and Takeru Wakasawa, and Miho Funabashi, and Akimasa Fukushi, and Masaharu Fujita, and Kiyoto Motojima, and Ikumi Tamai
October 1994, The Journal of biological chemistry,
Tomoji Maeda, and Takeru Wakasawa, and Miho Funabashi, and Akimasa Fukushi, and Masaharu Fujita, and Kiyoto Motojima, and Ikumi Tamai
February 2001, Nihon rinsho. Japanese journal of clinical medicine,
Tomoji Maeda, and Takeru Wakasawa, and Miho Funabashi, and Akimasa Fukushi, and Masaharu Fujita, and Kiyoto Motojima, and Ikumi Tamai
November 2008, FEBS letters,
Tomoji Maeda, and Takeru Wakasawa, and Miho Funabashi, and Akimasa Fukushi, and Masaharu Fujita, and Kiyoto Motojima, and Ikumi Tamai
August 2006, Biochemical and biophysical research communications,
Tomoji Maeda, and Takeru Wakasawa, and Miho Funabashi, and Akimasa Fukushi, and Masaharu Fujita, and Kiyoto Motojima, and Ikumi Tamai
April 2014, Acta veterinaria Scandinavica,
Tomoji Maeda, and Takeru Wakasawa, and Miho Funabashi, and Akimasa Fukushi, and Masaharu Fujita, and Kiyoto Motojima, and Ikumi Tamai
October 1996, Endocrinology,
Tomoji Maeda, and Takeru Wakasawa, and Miho Funabashi, and Akimasa Fukushi, and Masaharu Fujita, and Kiyoto Motojima, and Ikumi Tamai
February 2018, Scientific reports,
Tomoji Maeda, and Takeru Wakasawa, and Miho Funabashi, and Akimasa Fukushi, and Masaharu Fujita, and Kiyoto Motojima, and Ikumi Tamai
June 2017, Drug metabolism and pharmacokinetics,
Copied contents to your clipboard!